9 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 32.0% per year over the past 5 years.
Financial health
Total debt ($1.5B) exceeds cash ($378M); net debt is $1.1B.
Total debt has grown in line with revenue (31.6% vs 32.0% per year).
Operating income covered interest expense -112.2× in the latest year.
The company is unprofitable; at its current free-cash-flow burn it has roughly 1.6 years of cash runway.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$982M
-$416M
64.5%
-44.5%
-$233M
$1.5B
$378M
2024
$739M
-$436M
60.8%
-60.0%
-$275M
$1.1B
$526M
2023
$564M
-$479M
59.7%
-100.1%
-$345M
—
$1.1B
2022
—
-$655M
—
—
-$387M
—
$142M
2021
—
-$385M
—
—
-$284M
—
$492M
2019
—
-$76M
—
—
-$66M
—
$143M
2018
—
-$85M
—
—
-$92M
—
$141M
2017
—
-$83M
—
—
-$79M
—
$72M
2016
—
-$46M
—
—
-$38M
—
—
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$302M
-$112M
65.2%
-40.2%
-$71M
$1.5B
$989M
Dec '25
$281M
-$128M
64.6%
-43.0%
-$54M
$1.5B
$378M
Sep '25
$265M
-$93M
64.7%
-37.3%
-$46M
$1.1B
$580M
Jun '25
$232M
-$100M
65.0%
-45.9%
-$66M
$1.1B
$629M
Mar '25
$203M
-$95M
63.3%
-54.6%
-$67M
$1.1B
$699M
Dec '24
$202M
-$111M
61.6%
-62.4%
-$83M
$1.1B
$526M
Sep '24
$191M
-$108M
61.1%
-61.3%
-$55M
—
$585M
Jun '24
$177M
-$103M
59.1%
-56.8%
-$99M
—
$934M
Mar '24
$168M
-$115M
61.2%
-59.2%
-$37M
—
$1.0B
Dec '23
—
-$187M
—
—
-$83M
—
$1.1B
Sep '23
—
-$86M
—
—
-$80M
—
$457M
Jun '23
—
-$73M
—
—
-$101M
—
$271M
Mar '23
—
-$134M
—
—
-$82M
—
$224M
Dec '22
—
-$140M
—
—
-$101M
—
$142M
Sep '22
—
-$162M
—
—
-$100M
—
$158M
Jun '22
—
-$229M
—
—
-$135M
—
$215M
Mar '22
—
-$123M
—
—
-$51M
—
$574M
Dec '18
—
-$25M
—
—
-$29M
—
$141M
Sep '18
—
-$24M
—
—
-$28M
—
$114M
Dec '17
—
-$15M
—
—
-$21M
—
$72M
Valuation over time
How the market has priced GH against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has risen from 5.2× (Jan '24) to 19.3× (Jun '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is GH growing its revenue and profit?
Over the past 5 years, Guardant Health, Inc.'s revenue has grown 32.0% per year. These are computed facts, not advice.
How much debt does GH have?
As of FY2025, Guardant Health, Inc. reported $1.5B of total debt against $378M of cash; operating income covered interest expense -112.2×.
What is GH's profit margin?
In FY2025, gross margin was 64.5%, operating margin -44.5%, and net margin -42.4%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.